FLASCO OncoPod

The treatment landscape for chronic lymphocytic leukemia (CLL) has transformed dramatically over the past decade, creating new opportunities and new questions for clinicians managing this increasingly complex disease. In this episode of the FLASCO OncoPod, FLASCO President Edgardo Santos, MD, FACP, FASCO, sits down with renowned CLL expert Javier Pinilla-Ibarz, MD, PhD, of Moffitt Cancer Center to...

Join Scott E. Jordan, MD, FACOG, gynecologic oncologist at Broward Health, as he breaks down the most important endometrial cancer updates presented at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting. In this episode, Dr. Jordan reviews promising new therapies, including emerging antibody-drug conjugates and novel hormonal treatment combinations, highlights exciting clinical trial re...

What does it take to successfully navigate the business of oncology while continuing to deliver exceptional patient care ? In this episode of the FLASCO OncoPod, Dr. Robin Zon joins Dr. Jorge Garcia for a thoughtful conversation about leadership, advocacy, and the launch of ASCO Edge, a new educational resource designed to help oncology professionals better understand the operational and business...

In this final episode of the FLASCO OncoPod series, Drs. Jaglal, Fu, and Shahzad shift focus to the long-term management of atypical hemolytic uremic syndrome (aHUS) in oncology patients. Building on the diagnostic and acute management discussions from earlier segments, the panel explores key considerations that guide care beyond the initial presentation . Topics include the role of genetic and co...

In this episode of the FLASCO OncoPod, Drs. Jaglal, Fu, and Shahzad explore the real-world challenges of managing suspected thrombotic microangiopathy (TMA) in oncology patients. Building on a complex multiple myeloma case introduced in Part 1, this segment focuses on acute decision-making in the hospital setting. The discussion highlights how to differentiate thrombotic thrombocytopenic purpura (...

Atypical hemolytic uremic syndrome (aHUS) in patients with malignancy or undergoing cancer-directed therapy is likely under-recognized , yet early identification can have a profound impact on patient outcomes. In this FLASCO OncoPod roundtable, Drs. Jaglal, Fu, and Shahzad examine the clinical realities of drug-induced and malignancy-associated aHUS, emphasizing the importance of maintaining a hig...

Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals, alongside Dr. Noman Ashraf, MD, of Tampa General Hospital Cancer Institute for the final installment of the Advancing Care in GI and Biliary Tract Cancers podcast series. This episode focuses on gastroesophageal adenocarcinoma (GEA), exploring the disease state, patient management strategies...

Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals, alongside Dr. Noman Ashraf of Tampa General Hospital Cancer Institute and Dr. Umair Majeed of Mayo Clinic in Jacksonville for the third installment of the Advancing Care in GI and Biliary Tract Cancers podcast series. This episode explores HER2-targeted agents in GI malignancies, with a focu...

Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals, alongside Dr. Paresh Patel and Dr. Masoumeh Ghayouri for the second installment of the Advancing Care in GI and Biliary Tract Cancers podcast series. This episode focuses on HER2 testing in biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA), two GI malignancies where HER2...

Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals and GI Oncologist Dr. Umair Majeed of Mayo Clinic in Jacksonville for the first installment of the Advancing Care in GI and Biliary Tract Cancers podcast series, focused on biliary tract cancers. The first in the series, this episode provides a comprehensive overview of biliary tract cancers,...

Join Dr. Edgardo Santos and Dr. Luis Raez for a practical discussion on first-line decision-making in EGFR-mutated lung cancer and how early treatment choices shape survival, sequencing, and patient experience. This episode explores why first-line therapy represents a critical window for long-term benefit , including the reality that many patients never reach later lines of treatment and the impor...

Join moderator Dr. Tiago Bianchi and an expert multidisciplinary panel, including Zilipah Cruz, MSN-RN, ONN-CG , Vanessa Sepulveda-Dominguez, RN, BSN , and Charlotte Martin, PharmD , for a deep dive into the essential non-clinical aspects of metastatic colorectal cancer (mCRC) care. This episode explores the critical role of the entire oncology team in addressing the Social Determinants of Health...

The mCRC Journey: Treatment Sequencing and Real-World Decisions (Epi. 2) Join medical oncologists Dr. Tiago Bianchi and Dr. Raji Shameem for Episode 2 of our "Voices in Colorectal Cancer" Series as they navigate the complex, guideline-based, and real-world treatment landscape for metastatic colorectal cancer (mCRC) . This episode delves into current practice, informed by key insights from a recent...

In this first episode of the "Voices in Colorectal Cancer" Series, medical oncologists Dr. Tiago Bianchi and Dr. Raji Shameem confront the dramatic shift in colorectal cancer (CRC) presentation, drawing on urgent, real-world data from a recent FLASCO survey. The Troubling Trend: Younger: 91% of clinicians report seeing more CRC cases in patients under age 50 , mirroring incidence spikes in Florida...

In this new OncoPod episode, Dr. Christopher R. Cogle (University of Florida) and Dr. Neil M. Iyengar (Winship Cancer Institute at Emory University) discuss an often-overlooked gap in oncology care - the absence of a structured, non-pharmaceutical treatment layer to help patients stay on therapy and recover stronger. Drawing on findings from the CHALLENGE trial ( NEJM , 2025) and their clinical ex...

In this episode, FLASCO leaders Maen Hussein, MD, and Wassim McHayleh, MD join the discussion to explore the evolving role of ESR1 mutation testing in metastatic breast cancer. They highlight how these mutations, both acquired and intrinsic, shape treatment decisions and influence patient outcomes. Drawing from real-world data and insights from FLASCO’s statewide survey, the conversation offers pr...

In this episode, Dr. Ariel Perez Perez and Dr. Jose Sandoval-Sus, two of the coauthors of the FLASCO Consensus on Operationalizing Bispecifics for Lymphoma in the Community Setting discuss the core findings and practical recommendations outlined in their paper, highlighting how bispecifics can be safely and effectively delivered in the community setting. They share their perspectives on why this w...

In this episode, Dr. Michael Jaglal, Dr. Maen Hussein, and Dr. Jorge Garcia come together to discuss paroxysmal nocturnal hemoglobinuria (PNH), a rare but serious hematologic condition. From clinical presentation and diagnostic challenges, to therapy, this expert panel shares real-world insights and strategies to improve patient outcomes. This content has been created independently and solely by F...

Join Dr. Rami Komrokji of Moffitt Cancer Center as he shares expert insights on current trends and considerations in the management of Myelodysplastic Syndromes (MDS).

Tune in as Dr. Tiago Biachi, MD, from Moffitt Cancer Center, explores the latest advancements in immunotherapy for gastroesophageal cancer. In this episode, he breaks down key clinical trial data, examines emerging treatment strategies, and discusses the evolving role of immunotherapy in improving patient outcomes. Don’t miss this expert insight into the future of cancer care!

Tune in for Part 2 of Updates in IDHm Gliomas with FLASCO Neuro-Oncology Captain, Ashley Ghiaseddin, MD, FAAN. This informative podcast covers current and emerging treatments, the evolving role of IDH inhibitors, and the key challenges in treatment, including resistance and tumor heterogeneity. Whether you’re a clinician, researcher, or oncology professional, this FLASCO OncoPod provides valuable...

Join FLASCO for Part I of Updates in IDHm Gliomas with FLASCO Neuro-Oncology Captain, Ashley Ghiaseddin, MD, FAAN. This informative podcast covers current and emerging treatments, the evolving role of IDH inhibitors, and the key challenges in treatment, including resistance and tumor heterogeneity. Whether you’re a clinician, researcher, or oncology professional, this FLASCO OncoPod provides valua...

In this installment of the FLASCO OncoPod , we explore the critical role of Minimal Residual Disease (MRD) testing in advancing cancer care with Dr. Ivan Borrello , a distinguished oncologist from Tampa General Hospital . Dr. Borrello dives into the science behind MRD testing, its applications in hematologic malignancies, and how it informs treatment decisions and long-term patient outcomes. Gain...

In this episode of the FLASCO OncoPod , we are joined by renowned oncologist Dr. Edgardo Santos , MD, FACP, FCCP, FASCO, from The Oncology Institute of Hope and Innovation (TOI) to discuss the latest updates in lung cancer care. Dr. Santos shares insights into groundbreaking research, advancements in treatment protocols, and the evolving landscape of lung cancer management. From targeted therapies...

In this episode of the FLASCO OncoPod , we delve into the Management and Treatment of Polycythemia Vera (PV) with expert insights from Dr. Andrew Kuykendall , a leading hematologist from Moffitt Cancer Center . Join us as Dr. Kuykendall explores the latest advancements in PV care, including symptom management, therapeutic strategies, and emerging research that is shaping the future of treatment. W...